Skip to main content

Table 1 Characteristics of participants at baseline. BB, beta-adrenoceptor blocker; NBB, nonselective beta-adrenoceptor blockers; SD, Standard deviation; BMI, Body mass index

From: Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidence

Characteristic

Treated with BBs (n = 33,180)

Treated without BBs (n = 72,583)

Treated with NBBs (n = 4929)

Treated without NBBs (n = 100,834)

Age at recruitment (years), mean (SD)

61.0(6.5)

60.6(6.5)

58.5(7.6)

60.8(6.4)

Sex, %

 Female

47.9

42.9

59.9

45.7

 Male

52.1

57.1

40.1

54.3

BMI (kg/m2), mean (SD)

29.5(5.2)

29.6(5.3)

28.4(5.3)

29.6(5.3)

Race

 White, %

94.9

92.8

95.3

93.4

 Non-white, %

5.1

7.2

4.7

6.6

Smoking status, %

 Never or Previous

89.9

91.2

88.4

90.9

 Current

7.7

6.6

9.4

6.8

 Unknown

2.4

2.3

2.2

2.3

Alcohol consumption frequency, %

 None

11.2

10.0

13.9

10.2

 Special occasions only

13.7

13.7

15.4

13.6

 1–3 Times a mouth

10.7

10.7

12.1

10.5

 1–2 Times a week

24.1

24.1

22.1

24.0

 3–4 Times a week

20.3

20.3

17.9

20.8

 Daily or almost daily

19.8

19.8

18.7

21.0

Socioeconomic status (Townsend deprivation score), mean (SD)

 − 1.0(3.2)

 − 1.1(3.2)

 − 1.0(3.2)

 − 1.1(3.2)

Incomes score, mean (SD)

0.13(0.1)

0.12(0.1)

0.12(0.1)

0.13(0.1)

Health score, mean (SD)

0.05(0.9)

 − 0.02(0.8)

0.02(0.9)

0.01(0.9)

Education score, mean (SD)

18.5(17.7)

17.1(17.0)

17.5(17.3)

17.5(17.2)

Anxiety, %

59.5

57.7

68.4

57.8

Diabetes,%

8.3

7.0

4.9

7.6

Hyperlipidemia,%

19.7

8.2

8.5

12.0

Cerebrovascular diseases,%

2.5

2.1

1.9

2.2

Hypertension,%

54.0

55.7

35.6

56.1